TY - JOUR T1 - Systemic and Genetic Risk Factors for Reticular Macular Disease and Soft Drusen in Age-Related Macular Degeneration JF - medRxiv DO - 10.1101/2021.09.27.21263712 SP - 2021.09.27.21263712 AU - Robert J. Thomson AU - Joshua Chazaro AU - Oscar Otero-Marquez AU - Gerardo Ledesma-Gil AU - Yuehong Tong AU - Arielle C. Coughlin AU - Zachary R. Teibel AU - Sharmina Alauddin AU - Katy Tai AU - Harriet Lloyd AU - Maria Scolaro AU - Arun Govindaiah AU - Alauddin Bhuiyan AU - Mandip S. Dhamoon AU - Avnish Deobhakta AU - Jagat Narula AU - Richard B. Rosen AU - Lawrence A. Yannuzzi AU - K. Bailey Freund AU - R. Theodore Smith Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/29/2021.09.27.21263712.abstract N2 - Purpose Soft drusen and subretinal drusenoid deposits (SDD) aka reticular macular disease (RMD) characterize two pathways to advanced age-related macular degeneration (AMD). We propose these pathways are distinct diseases, with distinct genetic risks, serum risks and associated systemic diseases.Methods 126 Subjects with AMD had: retinal imaging for RMD status, serum risks, genetic testing, and histories of cardiovascular disease (CVD) and stroke.Results 62 subjects had RMD, 64 were nonRMD (drusen only), 51 had CVD or Stroke. RMD correlated significantly with: ARMS2 risk allele (p= 0.019); lower mean serum HDL (61±18 vs. 69±22 mg/dl, p= 0.038, t test); CVD and troke (34/51 RMD, p= 0.001).NonRMD correlated/trended with APOE2 (p= 0.032) and CETP (p= 0.072) risk alleles. 97 subjects total had some drusen, which correlated with CFH risk (p= 0.016). Multivariate independent risks for RMD were: CVD and Stroke (p= 0.008), and ARMS2 homozygous risk (p= 0.038).Conclusion The RMD and soft drusen AMD pathways have distinct systemic associations, serum and genetic risks. RMD is associated with CVD and stroke, ARMS2 risk, and lower HDL; drusen with CFH risk and two lipid risk genes. These pathways appear to be distinct diseases leading to advanced AMD.Summary Statement Two phenotypes of age-related macular degeneration, soft drusen and reticular macular disease (the combination of subretinal drusenoid deposits and choriocapillaris insufficiency), are shown here to have distinct systemic vascular, serum, and genetic risks. These findings support the concept that these phenotypes actually represent distinct disease processes.Competing Interest StatementRichard B. Rosen is a consultant to OptoVue, Boehringer-Ingelheim, Astellas, Genentech-Roche, NanoRetina, OD-OS, Regeneron, Bayer, Diopsys and Teva. He has personal financial interests in Opticology, Guardion and CellView. K. Bailey Freund is a consultant to Regeneron, Allergan, Zeiss, Bayer, Heidelberg Engineering and Novartis. He receives research funding from Genentech/Roche. R Theodore Smith is a consultant to Ora Technologies. The remaining authors have no relevant disclosures.Clinical TrialNCT04087356Funding StatementRegeneron Pharmaceuticals Investigator-Initiated Study, Research to Prevent Blindness Challenge Grant, Macula Foundation (KBF), Bayer-Global Ophthalmology Awards (GLG), International Council of Ophthalmology-Alcon Fellowship (OOM), New York Eye and Ear Infirmary Foundation (SA).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review board of Mount Sinai School of Medicine approved the study, which adhered to the tenets of the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesn/a ER -